Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: A systematic review

European Journal of Public Health

Volumn 24, Issue 5, 2013, Pages 781-788

  Jones, Lisa ^a   Bates, Geoff ^a   McCoy, Ellie ^a   Beynon, Caryl ^a   McVeigh, James ^a   Bellis, Mark A ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ATTITUDE TO HEALTH; EUROPE; HEALTH PROMOTION; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; MIDDLE AGED; PROCEDURES; PROGRAM EVALUATION; RISK; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ADULT; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HEPATITIS C; HUMANS; MIDDLE AGED; PROGRAM EVALUATION; RISK; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84923111144     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckt156     Document Type: Article

References (38)

1. World Health Organization. Hepatitis C. Fact sheet No. 164. Geneva: World Health Organization, 2011.
2. World Health Organization Regional Office for Europe. Hepatitis 2013. Available at: www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/hepatitis (10 October 2013, date last accessed
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
4. Mühlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34.
5. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):1-16.
6. Morris K. Tackling hepatitis C: a tale of two countries. Lancet 2011;377:1227-8.
7. Agarwal K, Cross TJS, Gore C. Chronic hepatitis C. BMJ 2007;334:54-5.
8. European Liver Patients Association. Report on Hepatitis Patient Self-Help in Europe by the European Liver Patients Association (ELPA). 2010.
9. Wilkinson M, Crawford V, Tippet A, et al. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009;29:29-37.
10. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138:123-35.
11. National Centre in HIV Epidemiology and Clinical Research. Australian NSP survey: national data report 2003-2007. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2008.
12. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33:126-33.
13. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009;16:352-8.
14. National Institute for Health and Clinical Excellence. Methods for the development of NICE public health guidance (second edition). London: National Institute for Health and Clinical Excellence, 2009.
15. Jackson R, Ameratunga S, Broad J, et al. The GATE frame: critical appraisal with pictures. Evid Based Med 2006;11:35-8.
16. Wilson DB.Practical Meta-Analysis Effect Size Calculator. Available at: www.campbellcollaboration.org/resources/effect-size-input.php (2 August 2013, date last accessed
17. Anderson EM, Mandeville RP, Hutchinson SJ, et al. Evaluation of a general practice based hepatitis C virus screening intervention. Scott Med J 2009;54:3-7.
18. Cullen BL, Hutchinson S, Cameron S, et al. Identifying former injecting drug users infected with Hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health 2011;34:14-23.
19. Hickman M, McDonald T, Judd A, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat 2008;15:250-4.
20. Roudot-Thoraval F, Monnet E, Marcet P, et al. Stratégies de dépistage de l'hépatite virale C en Médecine générale. Résultats d'un essai randomisé bicentrique. (Strategies of hepatitis C virus screening in general practice. A two-centre randomized trial). Gastroenterol Clin Biol 2000;11:1037-41.
21. Sahajian F, Bailly F, Vanhems P, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health 2011;33:182-92.
22. Helsper CW, van Essen GA, Bonten MJ, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract 2010;27:328-32.
23. Cullen W, Stanley J, Langton D. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. Br J Gen Pract 2006;56:848-56.
24. Rosenberg SD, Goldberg RW, Dixon LB, et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv 2010;61:885-91.
25. Cullen W, Kelly Y, Stanley J, et al. Experience of hepatitis C among current or former heroin users attending general practice. Ir Med J 2005;98:73-4.
26. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010;24:753-62.
27. Temple-Smith M, Gifford S, Stoov Eacute M. The lived experience of men and women with hepatitis C: implications for support needs and health information. Aust Health Rev 2004;27:46-56.
28. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010;17:839-44.
29. Martin NK, Vickerman P, Foster GR. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54:1137-44.
30. Castelnuovo E, Thompson-Coon J, Pitt M, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006;10:1-112.
31. Thompson Coon J, Castelnuovo E, Pitt M, et al. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006;23:393-406.
32. Hagedorn H, Dieperink E, Dingmann D, et al. Integrating hepatitis prevention services into a substance use disorder clinic. J Subst Abuse Treat 2007;32:391-8.
33. Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010;4:20-6.
34. Jack K, Willott S, Manners J, et al. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009;29:38-45.
35. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011;23:23-31.
36. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction 2004;99:621-33.
37. Defossez G, Verneau A, Ingrand I, et al. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008;20:367-72.
38. Craine N, Parry J, O'Toole J, et al. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. J Viral Hepat 2009;16:219-22.